President-elect Trump's threat to tariff Denmark if it resists his acquisition plans for the island territory of Greenland could disrupt one export that is wildly popular in America: Ozempic.

Trump added Denmark to his growing list of tariff targets — including Canada, Mexico and China — as he has increasingly spoken of the U.S. taking Greenland off Denmark's hands.

Danish multinational pharmaceutical giant Novo Nordisk is the sole owner of semaglutide, the active ingredient in both Ozempic and Wegovy. A month’s supply of Ozempic is close to $1,000 without insurance, though manufacturer coupons and patient assistance programs are available.

Novo Nordisk was estimated to be responsible for half of Denmark’s gross domestic product growth in 2024.

According to census data available through November, pharmaceutical products accounted for roughly 30 percent of Danish imports coming in through U.S. ports in 2024.

Polling from KFF last year found that 1 in 8 U.S. adults said they’ve tried a GLP-1 drug like Ozempic, including nearly half of those with diabetes and a quarter of people with heart disease.

When reached for comment, a Novo Nordisk spokesperson would not........

© The Hill